EP Wealth Advisors LLC Acquires Shares of 2,621 Krystal Biotech, Inc. $KRYS

Key Points

• EP Wealth Advisors LLC acquired a new position in Krystal Biotech, purchasing 2,621 shares valued at approximately $473,000 during the first quarter.
• Insider Suma Krishnan sold 1,389 shares of Krystal Biotech, decreasing their ownership stake by 0.09%; insiders have sold a total of 49,800 shares worth $7.5 million over the last quarter.
• Krystal Biotech reported $1.29 EPS for the last quarter, exceeding analysts' expectations, and has a current consensus rating of "Moderate Buy" with a target price of $210.38.

EP Wealth Advisors LLC bought a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 2,621 shares of the company's stock, valued at approximately $473,000.

Several other institutional investors also recently modified their holdings of the company. Brooklyn Investment Group grew its holdings in shares of Krystal Biotech by 291.7% during the 1st quarter. Brooklyn Investment Group now owns 141 shares of the company's stock worth $25,000 after purchasing an additional 105 shares in the last quarter. Twin Tree Management LP acquired a new stake in shares of Krystal Biotech during the 1st quarter worth approximately $29,000. Fifth Third Bancorp grew its holdings in shares of Krystal Biotech by 159.1% during the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after purchasing an additional 105 shares in the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of Krystal Biotech by 128.3% during the 1st quarter. Smartleaf Asset Management LLC now owns 315 shares of the company's stock worth $58,000 after purchasing an additional 177 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of Krystal Biotech during the 1st quarter worth approximately $74,000. Institutional investors and hedge funds own 86.29% of the company's stock.

Krystal Biotech Trading Down 0.5%

KRYS stock traded down $0.68 during trading on Friday, hitting $143.68. The company had a trading volume of 350,777 shares, compared to its average volume of 250,236. The company has a fifty day moving average price of $146.81 and a two-hundred day moving average price of $152.74. The company has a market cap of $4.16 billion, a P/E ratio of 29.20 and a beta of 0.66. Krystal Biotech, Inc. has a fifty-two week low of $122.80 and a fifty-two week high of $207.84.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported $1.29 EPS for the quarter, beating the consensus estimate of $1.08 by $0.21. The business had revenue of $96.04 million for the quarter, compared to analyst estimates of $95.42 million. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%. On average, analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 13,435 shares of Krystal Biotech stock in a transaction on Monday, July 14th. The stock was sold at an average price of $150.30, for a total value of $2,019,280.50. Following the completion of the transaction, the insider owned 1,443,276 shares in the company, valued at approximately $216,924,382.80. The trade was a 0.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders sold 49,800 shares of company stock valued at $7,487,943. Insiders own 13.70% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on KRYS shares. HC Wainwright reissued a "buy" rating and set a $240.00 price objective on shares of Krystal Biotech in a report on Friday, August 22nd. Chardan Capital decreased their price objective on Krystal Biotech from $219.00 to $216.00 and set a "buy" rating on the stock in a report on Friday, August 22nd. Citigroup reissued a "neutral" rating and set a $166.00 price objective (down previously from $176.00) on shares of Krystal Biotech in a report on Tuesday, August 5th. Finally, Bank of America decreased their price objective on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a report on Tuesday, July 22nd. Six equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $209.00.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).